JPRN-UMIN000050552招募中Unknown
Efficacy of osimertinib in advanced EGFR-mutated non-small cell lung cancer in first-line and second-line therapy (Tokushukai REAl-world Data project: TREAD 01) - Efficacy of osimertinib in advanced EGFR-mutated non-small cell lung cancer in first-line and second-line therapy (Tokushukai REAl-world Data project: TREAD 01)
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •EExclusion criteria include: de novo EGFR T790 M mutation, active multiple cancers, failure to provide informed consent (opting to opt-out), poor data extraction (e.g., missing details of previous cancer treatment at other hospitals or individual patient data), simultaneous and metachronous double cancers other than in situ/intramucosal cancer cured by local treatment or endoscopic lesions diagnosed as in situ cancer, and disease-free for 5 years or less.
研究者
相似试验
招募中
1 期
ovel treatment for people with lung cancer harbouring a specific mutatioEUCTR2018-001863-21-NOVestre Viken Hospital Trust100
进行中（未招募）
1 期
ovel treatment for people with lung cancer harbouring a specific mutatioEUCTR2018-001863-21-LTVestre Viken Hospital Trust100
进行中（未招募）
1 期
ovel treatment for people with lung cancer harbouring a specific mutatioEUCTR2018-001863-21-DKVestre Viken Hospital Trust20
已完成
2 期
ncommon EGFR mutations conducted with Osimertinib in patients with NSCLC: A phase 2 studyAdvanced / recurrent non-small cell lung cancer (NSCLC)JPRN-jRCTs071200002Kubota Kaoru40
已完成
不适用
Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)JPRN-UMIN000029763Kobe City Medical Center General Hospital Department of medical oncology6